Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases. We create distinct and transformative treatments for endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following product candidates:

• Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia
• MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause